RxSight, Inc. (NASDAQ:RXST) Shares Purchased by Voloridge Investment Management LLC

Voloridge Investment Management LLC increased its stake in shares of RxSight, Inc. (NASDAQ:RXST - Free Report) by 138.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 365,617 shares of the company's stock after buying an additional 212,599 shares during the quarter. Voloridge Investment Management LLC owned 0.91% of RxSight worth $12,570,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the business. Barclays PLC grew its stake in RxSight by 389.8% in the third quarter. Barclays PLC now owns 58,786 shares of the company's stock valued at $2,906,000 after acquiring an additional 46,783 shares during the period. KBC Group NV increased its stake in shares of RxSight by 71.0% during the fourth quarter. KBC Group NV now owns 2,107 shares of the company's stock worth $72,000 after purchasing an additional 875 shares during the period. Van ECK Associates Corp grew its position in RxSight by 46.7% during the fourth quarter. Van ECK Associates Corp now owns 3,265 shares of the company's stock worth $112,000 after buying an additional 1,040 shares in the last quarter. Rhumbline Advisers grew its position in RxSight by 3.6% during the fourth quarter. Rhumbline Advisers now owns 48,473 shares of the company's stock worth $1,666,000 after buying an additional 1,663 shares in the last quarter. Finally, Principal Financial Group Inc. boosted its holdings in shares of RxSight by 10.8% in the 4th quarter. Principal Financial Group Inc. now owns 39,925 shares of the company's stock valued at $1,373,000 after purchasing an additional 3,879 shares in the last quarter. Institutional investors own 78.78% of the company's stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on RXST. UBS Group downgraded RxSight from a "buy" rating to a "neutral" rating and cut their price objective for the company from $45.00 to $16.00 in a report on Wednesday, April 9th. Wells Fargo & Company upgraded RxSight from an "equal weight" rating to an "overweight" rating and lifted their price target for the company from $17.00 to $25.00 in a research note on Monday, May 19th. Needham & Company LLC restated a "buy" rating and issued a $43.00 target price on shares of RxSight in a research note on Thursday, April 3rd. Stifel Nicolaus lowered their target price on shares of RxSight from $33.00 to $28.00 and set a "hold" rating on the stock in a report on Wednesday, March 19th. Finally, JPMorgan Chase & Co. reiterated an "underweight" rating and issued a $17.00 price objective (down previously from $40.00) on shares of RxSight in a research report on Friday, April 4th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, RxSight has an average rating of "Hold" and a consensus target price of $37.90.

Insider Activity at RxSight

In other news, Director Tamara Fountain sold 7,000 shares of the company's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $25.71, for a total value of $179,970.00. Following the completion of the transaction, the director now owns 24,793 shares in the company, valued at approximately $637,428.03. This represents a 22.02% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 9.36% of the company's stock.

RxSight Trading Down 0.8%

Shares of RXST traded down $0.13 during mid-day trading on Thursday, hitting $15.97. The company's stock had a trading volume of 104,622 shares, compared to its average volume of 688,497. The firm has a market capitalization of $649.09 million, a price-to-earnings ratio of -19.10 and a beta of 1.32. The company's 50-day moving average is $16.57 and its 200-day moving average is $28.31. RxSight, Inc. has a 52-week low of $12.53 and a 52-week high of $61.10.

RxSight (NASDAQ:RXST - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.03) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.03). The business had revenue of $37.90 million for the quarter, compared to the consensus estimate of $38.74 million. RxSight had a negative net margin of 23.92% and a negative return on equity of 14.00%. The company's revenue was up 28.5% compared to the same quarter last year. During the same period last year, the firm posted ($0.25) earnings per share. As a group, sell-side analysts predict that RxSight, Inc. will post -0.7 earnings per share for the current fiscal year.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.